HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Dr John V Heymach, including the following topics: Overview of the biology and treatment landscape of HER2-mutant non-small cell lung cancer (NSCLC) (0:00) Datasets evaluating trastuzumab deruxtecan for HER2-mutant NSCLC (5:03) Clinical data with zongertinib for HER2-mutant NSCLC (6:35) Emerging data with sevabertinib for HER2-mutant NSCLC (14:41) Other investigational strategies being evaluated for HER2-mutant NSCLC (19:10) Summary of the current and future treatment landscape of HER2-mutant NSCLC (21:52) CME information and select publications